ReviewFrontiers in immunology2026
Surfactant protein D: prognostic insights and emerging therapeutic roles in cancer.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Surfactant protein D (SP-D), a C-type lectin found at the mucosal surfaces, plays crucial roles in innate immunity and homeostasis of the lung. In addition to the lungs, extra-pulmonary expression of SP-D has been reported in several tissues. Differential expression of SP-D in lung adenocarcinoma and metastases implicated its importance in diagnosis and prognosis. Serendipitous discovery of the direct anti-tumor effect of SP-D in human eosinophilic leukemia and breast cancer cells opened the field for exploring its therapeutic potential in various cancers and its contribution to immunomodulatory mechanisms. The current review discusses the role of SP-D as a prognostic marker in lung, breast, gastrointestinal, pancreatic, ovarian and prostate cancer. Additionally, levels of SP-D in serum and bronchoalveolar lavage enable diagnosis and assessment of the risk of developing lung cancer. The molecular interaction of SP-D with Epidermal Growth Factor Receptor and Glucose-Related Protein 78, induction of cell cycle arrest and activation of the intrinsic apoptosis pathways are some of the salient mechanisms contributing to the immune surveillance of tumor cells by SP-D. The review also discusses SP-D interactions with oncogenic pathogens and therapeutic potential of recombinant SP-D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.